1 / 28

REGIONAL AND INTRAREGIONAL CLUSTERS

REGIONAL AND INTRAREGIONAL CLUSTERS. NOVUM RESEARCH PARK. 1972 Huddinge University Hospital 1985-91 Novum Research Foundations Center for Biotechnology Center for Nutrition & Toxicology Center for Structural Biochemistry

ramla
Download Presentation

REGIONAL AND INTRAREGIONAL CLUSTERS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. REGIONAL AND INTRAREGIONAL CLUSTERS

  2. NOVUM RESEARCH PARK 1972 Huddinge University Hospital 1985-91 Novum Research Foundations Center for Biotechnology Center for Nutrition & Toxicology Center for Structural Biochemistry Center for Oral Biology Founders: Stockholm County Council & Karolinska Institute Purpose: To create a biomedical center of excellence 1985 - R&D companies in and near Novum. Expanison of research Improvements of infrastructure (communications, hotel, shops) 1989 Novum Research Center 1997 - 02 University of Södertörn 2000 - Planning for Novum BioCity

  3. NOVUM RESEARCH PARK A.D. 2002A qualified environment for front-line research and for the establishment and growth of research-based companies Novum Research Foundations (4 foundations ~ 350 employees)biomedical basic research Departments & Centers of Research(~ 350 employees) Karolinska Institute, Huddinge University Hospital, Södertörn University biomedical & medical technology research Research Companies(20 companies, ~ 450 employees) Novum Business Development Group business counselling, strategic planning information & visitor’s service

  4. NOVUMPRECLINICAL RESEARCH • Nuclear receptors • Signal transduction • Molecular genetics • Molecular nutrition • Molecular immunology • Structural biochemistry

  5. NOVUMCLINICAL RESEARCH • Cancer Osteoporosis • Metabolic disorders Alzheimer’s disease • Cellular therapy Virus infection (Hepatitis) • Gene therapy

  6. NEIGHBOURS AND PARTNERS IN NOVUM RESEARCH PARK • HUDDINGE UNIVERSITY HOSPITAL • THE KAROLINSKA INSTITUTET MEDICAL SCHOOL • SÖDERTÖRN UNIVERSITY COLLEGE • SERVICE COMPANIES (about 25) _______________________ Appr. 17.000 personer (employees & students) working daily in the park area

  7. BUSINESS COUNSELLING IN NOVUM Patenting Licensing Business law Market analysis Business Planning Financing

  8. NOVUM’SRESEARCH COMPANIES Multinationals AstraZeneca Pain Control Research Baxter Medical Renal Function Research Sumitomo Pharmaceuticals Alzheimer’s disease

  9. R&D specialists Karo Bio Receptor biology Medivir HIV & Herpes antivirals Tripep HIV antivirals LightUp Technologies DNA probe technology / diagnostics Avaris Gene vector technolog Oxypharma Rheumatoid Arthritis Novum’s Research Companies

  10. NOVUM’S RESEARCH COMPANIES Service & Technology providers • CyberGene Sequencing, genetic diagnostics • Nova Snitt Analysis Histology • SciBase Impedance analysis of skin & mucosa • Innomed-Konsult Design of GMP facilities

  11. NOVUM BIOCITY

  12. NOVUM BIOCITY

  13. NOVUM RESEARCH PARK

  14. Nuclear Receptors Hormones or Metabolic Intermediates Changed Cell Function Protein Nuclear Receptor Target gene • Large family of receptors • Important drugs on the market • Validated drug targets • Bind hormones with high affinity • New technology and receptors offer improved treatments and new indications

  15. LXRNew Promising Target for Atherosclerosis • Upregulates cholesterol pump (ABCA1) • Upregulates APO-E in macrophages • Upregulates 7-hydroxylase (cholesterol break down)

  16. Atherosclerosis Treatedbloodvessel LXR Concept to Treat Atherosclerosis Drug compound stimulates LXRactivity LXR stimulates synthesis of ABC1protein + ABC1-protein LXR Cell ABC1 removes harmful cholesterol Tangier disease;non-functional ABC-1 leads to atherosclerosis

  17. Karo Bio – Leader in Nuclear Receptor and Proteomics-Based Drug Discovery

  18. BMS Merck AHP Abbott Boehringer Ingelheim Bayer AG GPC Biotech NovImmune S.A. Serono International Aventis Karo Bio AB Stockholm Karo Bio USA, Inc. Durham, NC KaroBio,Inc. San Francisco

  19. Develop pharmaceuticals for major markets Be a leading company within the field of nuclear receptors and proteomics-based drug discovery Conduct clinical development and marketing through partners and licensees Finance operations through partnerships Business Concept

  20. Up-front payment Target identification Revenue Model of Karo Bio Royalty on sales Research funding R&D milestones Drug discovery Pre-clinical development Clinical development Market

  21. Strategic Position KARO BIO Scientific network Partners Karolinska Insitutet UCSF Duke University University of Bochum Sahlgrenska Hospital University of York … Abbott Laboratories Bristol-Myers Squibb Merck & Co, Inc. Aventis …

  22. Nuclear Receptor Project Portfolio Target and indication validation …...C l i n i c a l D e v e l o p m e n t…... Drug discovery Preclinical Development Phase I Phase II Phase III NDA THR Obesity BMS ER Merck LXRAHP 2 1 1 2 GR Diabetes Abbott THR Cardiac arrhythmia /KB THR 015/Cardiac arrhythmia/KB THR KB2611/ Skin atrophy /KB AR Prostate cancer /KB MR Heart failure /KB THR Glaucoma/KB GR Inflammation /KB Anti-microbials/KB

  23. Karo Bio has a diverse nuclearreceptor research portfolio Clinical development NDA/ Market Diseasearea Drug discovery Preclinicaldevelopment Phase I Phase II Phase III Athero-sclerosis 100 MUSD + Royalties Oestrogen receptor 80 MUSD + Royalties Type II diabetes 56 MUSD + Royalties 40 MUSD + Royalties Obesity Karo Bio has four profitable nuclear receptor collaborations in potential block-buster areas

  24. Några reflektioner kring ett nytt paradigm för medicinsk och bioteknisk forskning • Avståndet mellan laboratoriebänken och patientens säng har minskat betydligt och minskar allt snabbare i takt med den nya molekylärbiologiska forskningens landvinningar • Enda sättet att föra över forskningsresultat från lab.bänken till patienten går via patentering och kommersialisering • Den nutida laboratorieforskaren har ett etiskt imperativ att börja arbeta i denna riktning (modern tillämpning av den Hippokratiska eden!)

  25. Några reflektioner…… (forts.) • Det nya paradigmet för medicinsk/naturvetenskaplig forskning består i en trestegsraket, akademi, SMEs samt stora företag, där de två första stegen bör samlokaliseras under ett tak • I detta cluster kommer nya forskningsstrategier och forskningstekniker att växa fram samtidigt som nya utbildningslinjer med kombinationer av bioteknik, medicin, ekonomi, juridik, etik mm kommer att utvecklas • Allt detta betyder effektivare forskning, större konkurrenskraft i ett internationellt perspektiv samt bättre ekonomi för Sverige

More Related